Premium
Combination Chemotherapy for Malignant Mixed Germ Cell Tumours of the Ovary: A Prospective Study
Author(s) -
Singh Pritam,
Yordan Edgardo L.,
Graham James R,
Wilbanks George D.,
Slayton Robert E.,
Miller Alexander W.
Publication year - 1988
Publication title -
asia‐oceania journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 0389-2328
DOI - 10.1111/j.1447-0756.1988.tb00084.x
Subject(s) - chemotherapy , bleomycin , vincristine , vinblastine , medicine , cisplatin , cyclophosphamide , combination chemotherapy , laparotomy , ovary , stage (stratigraphy) , oncology , germ cell tumors , germ cell , surgery , biology , paleontology , biochemistry , gene
A prospective study of 10 patients with malignant mixed germ cell tumours of the ovary treated with combination chemotherapy consisting of either vincristine, actinomycin D and cyclophosphamide (VAC) or vinblastine, bleomycin and cisplatin (VBP) is reported. The median age of these patients was 21.5 years and 3 patients had Stage I disease, 4 Stage II and 3 had Stage III disease. A detailed analysis of the pathological and prognostic features of mixed germ cell tumours is presented. Six of these patients are alive and well for periods ranging from 2 to 10 years. Contemporary management of these tumours with chemotherapy including the role of second‐look laparotomy and second‐line chemotherapy is discussed. Optimal therapy of these tumours consists of surgery followed by combination chemotherapy.